May 06, 2020
Theravance Biopharma, Inc. Reports First Quarter 2020 Financial Results and Provides Business Update
Apr 28, 2020
Theravance Biopharma to Report First Quarter 2020 Financial Results on May 6, 2020
Apr 23, 2020
Theravance Biopharma Announces First Subject Dosed in Phase 1 Study of TD-0903, in Development for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19
Apr 20, 2020
Theravance Biopharma Announces Peer-Reviewed Publication Highlighting TD-1473 Program in the Journal of Crohn's and Colitis
Feb 24, 2020
Theravance Biopharma, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
Feb 18, 2020
Theravance Biopharma Announces Presentations at Upcoming Investor Conferences
Jan 07, 2020
Theravance Biopharma Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference
Dec 23, 2019
Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program
Dec 03, 2019
Theravance Biopharma Announces Dosing of First Patient in Phase 2 Allergen Challenge Study of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases
Nov 06, 2019
Theravance Biopharma to Present at the 2019 Credit Suisse Healthcare Conference
Oct 29, 2019
Theravance Biopharma to Report Third Quarter 2019 Financial Results on November 5
Oct 21, 2019
Theravance Biopharma and Mylan to Present New Data on YUPELRI® (revefenacin) at the 2019 CHEST Annual Meeting
Sep 25, 2019
Theravance Biopharma to Present at the 2019 Cantor Global Healthcare Conference
Aug 28, 2019
Theravance Biopharma to Present at Two Upcoming Investor Conferences
Jul 31, 2019
Theravance Biopharma, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update
Jul 22, 2019
Theravance Biopharma Reports New Data from Phase 2 Study of Ampreloxetine (TD-9855) in Oral Presentation at 32nd European Neurology Congress
Jun 18, 2019
Theravance Biopharma Reports New Data from Phase 2 Study of Ampreloxetine (TD-9855) in Presentation at 2019 International Association of Parkinsonism and Related Disorders (IAPRD) World Congress
Jun 14, 2019
Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories
Jun 04, 2019
Theravance Biopharma Appoints Andrew Hindman as Senior Vice President and Chief Financial Officer
May 21, 2019
Theravance Biopharma Reports Data from Phase 1b Study of TD-1473 in Oral Presentation at Digestive Disease Week (DDW) 2019